Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | PREP | P48147 | 3/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1068219 | 0.69 | DPP4 (0.51) | DPP4DPP7 | |
| SCHEMBL1068220 | 0.69 | DPP4 (0.51) | DPP4DPP7 | |
| SCHEMBL4564247 | 0.63 | AR (0.40) | CHRM5CHRM1CHRM3MEN1NPC1 | |
| SCHEMBL5487719 | 0.62 | DPP4 (0.53) | DPP4DPP7 | |
| SCHEMBL4611151 | 0.62 | NAAA (0.46) | FAAHMEN1KMT2A | |
| SCHEMBL2304021 | 0.62 | NAAA (0.46) | FAAHMEN1KMT2A | |
| SCHEMBL3437063 | 0.61 | NAAA (0.59) | FAAH | |
| SCHEMBL3437061 | 0.61 | NAAA (0.59) | FAAH | |
| SCHEMBL6400131 | 0.61 | CYP1A2 (0.41) | — | |
| SCHEMBL6954266 | 0.61 | CYP1A2 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808168-B1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |